- Clone:
- REAL685
- Type of antibody:
- Releasable fluorochromes, Primary antibodies, Recombinant antibodies
- Applications:
- MICS, IF, IHC Glossary
- Select a conjugate:
Related products for Cytokeratin 18 Antibody, anti-human, REAdye_lease™
A
B
A
B
Clone REAL685 is an antibody fragment derived from the full Cytokeratin 18 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL685 specifically recognizes cytokeratin 18 (K18). Cytokeratins are located in the intracytoplasmic cytoskeleton of epithelial tissue. Cytokeratin 18 is frequently used in conjunction with keratin 8 and keratin 19 to differentiate cells of epithelial origin from hematopoietic cells and to enumerate circulating tumor cells in blood. Gene mutations of Keratin 18 lead in cryptogenic cirrhosis.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675)
KRT18, CK-18, Keratin-18, K18
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Oshima, R. G. et al. (1986) Comparison of mouse and human keratin 18: a component of intermediate filaments expressed prior to implantation. Differentiation 33 (1): 61-68
- Ku, N. O. et al. (2003) Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. Proc. Natl. Acad. Sci. U.S.A. 100 (10): 6063-6068
- Waseem, A. et al. (1990) Embryonic simple epithelial keratins 8 and 18: chromosomal location emphasizes difference from other keratin pairs. New Biol. 2 (5): 464-478